-
Media Release
Higher dose of Novartis drug Exelon® Patch approved by FDA for patients with mild to moderate Alzheimer's disease
-
Media Release
NPC Statement on Comments Made in Media Coverage of Paycheck Fairness Act
-
Media Release
NPC Statement on Comments Made in Media Coverage of Paycheck Fairness Act
-
Media Release
Two new analyses reinforce consistent efficacy of Novartis therapy Gilenya across wide range of relapsing MS patients
-
Media Release
Two new analyses reinforce consistent efficacy of Novartis therapy Gilenya across wide range of relapsing MS patients
-
Media Release
TV host Phil Keoghan and professional women cyclists join Novartis to raise awareness of multiple sclerosis
-
Media Release
TV host Phil Keoghan and professional women cyclists join Novartis to raise awareness of multiple sclerosis
-
Media Release
Higher dose of Novartis drug Exelon® Patch showed statistically significantly less decline in function in Alzheimer’s vs. lower dose
-
Media Release
Higher dose of Novartis drug Exelon® Patch showed statistically significantly less decline in function in Alzheimer’s vs. lower dose
-
Media Release
New extension study data with Novartis drug Gilenya shows patients successfully treated for up to 7 years in relapsing MS
-
Media Release
New extension study data with Novartis drug Gilenya shows patients successfully treated for up to 7 years in relapsing MS
-
Media Release
Novartis announces update to United States prescribing information for MS therapy Gilenya following FDA review